BNP Paribas Asset Management
OCUL icon

BNP Paribas Asset Management’s Ocular Therapeutix OCUL Stock Holding History

BNP Paribas Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74M Sell
441,775
-3,630
-0.8% -$34.6K ﹤0.01% 931
2025
Q4 		$5.41M Buy
445,405
+444,414
+44,845% +$5.4M 0.01% 819
2025
Q3 		$12K Hold
991
– – ﹤0.01% 1575
2025
Q2 		$9K Buy
+991
New +$7.76K ﹤0.01% 1816

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BNP Paribas Asset Management's OCUL Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Ocular Therapeutix (OCUL) stake by 0.81% in Q1 2026, selling an estimated $34.6K and leaving 441,775 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #931.

BNP Paribas Asset Management first reported a position in OCUL in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.41M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • BNP Paribas Asset Management held 441,775 shares of Ocular Therapeutix worth $3.74M as of Q1 2026.
  • BNP Paribas Asset Management sold 3,630 Ocular Therapeutix shares in Q1 2026, an estimated $34.6K.
  • Ocular Therapeutix made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #931 holding.
  • BNP Paribas Asset Management first reported a position in Ocular Therapeutix in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Ocular Therapeutix position peaked at $5.41M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.